CTLA4 and non-small cell lung carcinoma: Several large-scale, phase III trials have revealed survival benefits of PD-1 inhibitors alone or plus CTLA-4 inhibitors over standard-of-care chemotherapy.1,2 Chemoimmunotherapy has also served as first-line options for various cancers (e.g., NSCLC).